论文部分内容阅读
目的分析B淋巴细胞瘤-2(Bcl-2)、人乳头瘤病毒16/18(HPV16/18)、Survivin基因在宫颈癌及癌前病变即宫颈上皮内瘤样变(CIN)中的表达特征及临床意义。方法选取蚌埠医学院第一附属医院收治的118例宫颈癌及CIN患者作为研究组,另选取同期收治的80例宫颈良性病变患者作为对照组,采集两组患者的宫颈病变组织进行HPV16/18 DNA、Survivin mRNA、Bcl-2表达检测,将检测结果进行对比分析。结果研究组的Bcl-2、HPV16/18、Survivin阳性检出率均显著高于对照组,研究组中宫颈癌患者的Bcl-2、HPV16/18、Survivin阳性检出率又显著高于CIN患者,差异有统计学意义(χ2=80.726、107.551、83.089、18.653、23.157、21.732,P<0.05)。宫颈癌患者中组织低分化程度者的Bcl-2、HPV16/18及Survivin阳性率均显著高于中、高度分化患者,差异有统计学意义(χ~2=12.478、20.019、20.820,P<0.05);ⅠA、ⅠB、ⅡA期患者的Bcl-2、HPV16/18、Survivin阳性表达率对比差异均无统计学意义(χ~2=0.822、0.955、0.822,P>0.05);淋巴结转移患者的Bcl-2、HPV16/18、Survivin阳性表达率均显著高于无淋巴结转移者,差异有统计学意义(χ~2=37.864、36.560、36.260,P<0.05)。CINⅠ~Ⅱ级患者的Bcl-2、HPV16/18、Survivin阳性表达率均显著低于CINⅢ级患者,差异有统计学意义(χ2=38.405、44.524、25.793,P<0.05)。结论宫颈癌及CIN患者的Bcl-2、HPV16/18、Survivin均呈高表达,联合进行Bcl-2、HPV16/18、Survivin检测可为宫颈癌的诊断治疗提供一定的临床依据。
Objective To analyze the expression of Bcl-2, HPV16 / 18 and Survivin in cervical intraepithelial neoplasia and cervical intraepithelial neoplasia (CIN) And clinical significance. Methods A total of 118 cervical cancer patients and CIN patients admitted to the First Affiliated Hospital of Bengbu Medical College were enrolled as research group. Eighty patients with benign cervical lesions were selected as the control group. Cervical lesions in both groups were collected for HPV16 / 18 DNA , Survivin mRNA, Bcl-2 expression, the test results were compared. Results The positive rates of Bcl-2, HPV16 / 18 and Survivin in the study group were significantly higher than those in the control group. The positive rates of Bcl-2, HPV16 / 18 and Survivin in the study group were significantly higher than those in the CIN group , The difference was statistically significant (χ2 = 80.726,107.551,83.089,18.653,23.157,21.732, P <0.05). The positive rates of Bcl-2, HPV16 / 18 and Survivin in patients with low differentiation of cervical cancer were significantly higher than those in moderately and highly differentiated patients (χ ~ 2 = 12.478,20.019,20.820, P <0.05 ). There was no significant difference in the positive rates of Bcl-2, HPV16 / 18 and Survivin between ⅠA, ⅠB and ⅡA (χ ~ 2 = 0.822,0.955,0.822, P> 0.05) -2, HPV16 / 18 and Survivin were significantly higher than those without lymph node metastasis (χ ~ 2 = 37.864,36.560,36.260, P <0.05). The positive rates of Bcl-2, HPV16 / 18 and Survivin in patients with CINⅠ ~ Ⅱ were significantly lower than that of patients with CINⅢ (χ2 = 38.405,44.524,25.793, P <0.05). Conclusions The expressions of Bcl-2, HPV16 / 18 and Survivin in cervical cancer and CIN are all highly expressed. Combined detection of Bcl-2, HPV16 / 18 and Survivin may provide some clinical evidences for the diagnosis and treatment of cervical cancer.